AB0882 ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSIS

Background Studies have postulated that advanced glycation end products (AGEs) could a relevant role as inducers in the chronic inflammatory pathway present various diseases -- including systemic sclerosis (SSc). Similarly, concentration of AGEs maybe related to nailfold capillaroscopy SSc changes, diffuse skin subtype, or calcinosis. Validation studies shown autofluorescence is strongly levels biopsies. Objectives To characterize and identify association between concentrations AGEs, measured by cutaneous autofluorescence, disease parameters patients. Methods were (Age Reader Mu Connect from Diagnostics Technologies BV®) 179 patients correlated with demographic clinical data. Cumulated distributed tertiles. Categorical data was described frequencies, whereas continuous variables displayed mean (standard deviation). ANOVA tests conducted explore linear demographics features cumulated value. Regression models adjusted age (M1), also smoking status (M2 = M1 + smoker). Results Table 1 shows distribution correlation most characteristics studied according classified Male gender (p-value M1=0.008, M2=0.003) anticentromere antibodies (ACA) M1=0.010, M2=0.034) statistically significant associated higher levels. In addition, inversely obesity categorical variable statistical significance M1=0.036, M2=0.022). Although not significant, there trend towards values AGES 0.05 - 0.1) esophageal involvement manifestations (either limited subtype) lower prevalence anti-topoisomerase (ATA). No associations other found. Conclusion Higher independently male gender, ACA positivity obesity. might be involved aethiopathological pathways leading manifestations. Finally, mechanism obese indicate milder disease, they values, opposing what has been healthy subjects. This less severe gastrointestinal malnourishment. References [1]Murray, Andrea K., et al . The Journal Rheumatology 39.8 (2012): 1654-1658. [2]Kaloudi, O., 46.3 (2007): 412-416. [3]Davies, Christine A., 48.8 (2009): 876-882. [4]Meerwaldt R., Ann N Y Acad Sci 2005;1043:290–298. [5]Villanueva-Martin, G., J. Clin. Med. 2022, 11, 6014. 1. Correlations our cohort c: categorized; M1: for age; M2 tobacco. BMI: body mass index. * Not age. Bold indicates differences (p<0.05). All First tertile [1.4,2.4) Second [2.4,2.9] Third [2.9,6.7] p-value N=179 N=60 N=62 N=57 Gender (Male) 17 (9.5%) 4 (6.7%) 5 (8%) 8 (14%) 0.008 0.003 Age 61.0 (12.6) 55.7 (13.4) 61.7 (11.9) 65.8 (10.4) 0.000* Smoking 16 (8.94%) 2 (3.33%) 6 (9.68%) (14.0%) 0.031 Skin 161 (89.9%) 50 (83.3%) 58 (93.5%) 53 (93.0%) 0.100 0.085 Esophageal 155 (86,6) 49 (81,7%) 55 (88,7%) 51 (89,5%) 0.113 0.078 Anti-topoisomerase 21 (14.7%) 10 (20.4%) (11.8%) (11.6%) 0.076 0.071 Anti-centromere 70 (47.3%) (41.2%) 26 (50.0%) 23 (51.1%) 0.010 0.034 Obesity 39 (21.8%) 15 (25.0%) 14 (22.6%) (17.5%) 0.036 0.022 BMI 26.0 (5.42) 26.4 (6.20) 25.8 (4.91) (5.13) 0.457 0.603 cBMI: 0.370 0.387 Healthy 84 (47.5%) 28 (46.7%) 29 (48.3%) 27 (47.4%) Overweight 66 (37.3%) (35.0%) 22 (36.7%) (40.4%) (15.3%) 11 (18.3%) 9 (15.0%) 7 (12.3%) Acknowledgements Project “202022-33” funded FUNDACIÓ LA MARATÓ DE TV3 Disclosure Interests None Declared.